MESO Q4 2018 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+200.4% YoY

Gross Profit

-$421,000-24.8% margin

Operating Income

-$23M-1341.2% margin

Net Income

-$21M-1225.5% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+71.5%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$910,000

Balance Sheet

Total Assets

$692M

Total Liabilities

$146M

Stockholders' Equity

$546M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$566,000	+200.4%
Gross Profit	-$421,000	-$584,000	+27.9%
Operating Income	-$23M	-$23M	+2.4%
Net Income	-$21M	-$27M	+23.4%